RE:RE:RE:Is this TLT type liftoff after FDA IND approval?Oncology drugs, just like in any other industries, have their stock price set based on market valuation range, and that market valuation is based upon expected market shares, in terms of revenue.
_______________
nemo3 - (11/29/2019 2:47:08 PM) RE:RE:Is this TLT type liftoff after FDA IND approval? I would suspect we will see a jump in TLT after the much anticipated FDA news release comes out. I also suspect that a jump will be somewhat muted by the number of shares out. When the time arrives that we get results of this Ph2 study and they meet or exceed expectations, it will be very interesting to see where TLT's share price goes. Even with stellar results, shares outstanding will affect the price. At 35 million shares, success could have meant a $50 share price or more. With the number we currently have, I would think the max we get out of this is $5. Maybe $10. Of course, I would like $100 but would think that is unrealistic again given OS. What are other's thoughts on this?